A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1|[sol]|2 inhibitor, in advanced solid tumours

B A Wilky; M A Rudek; S Ahmed; D A Laheru; D Cosgrove; R C Donehower; B Nelkin; D Ball; L A Doyle; H Chen; X Ye; G Bigley; C Womack; N S Azad

首页> 外文期刊>British Journal of Cancer >A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1|[sol]|2 inhibitor, in advanced solid tumours

【24h】

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1|[sol]|2 inhibitor, in advanced solid tumours

机译：在晚期实体瘤中使用西妥妥珠单抗（抗IGF-1R抗体）和selumetinib（MEK 1 | [sol] | 2抑制剂）垂直抑制IGF信号的I期试验

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background:We completed a phase I clinical trial to test the safety and toxicity of combined treatment with cixutumumab (anti-IGF-1R antibody) and selumetinib (MEK 1/2 inhibitor).

机译：背景：我们完成了一项I期临床试验，以测试西昔单抗（抗IGF-1R抗体）和selumetinib（MEK 1/2抑制剂）联合治疗的安全性和毒性。

著录项

来源
《British Journal of Cancer》 |2015年第1期|共8页
作者
B A Wilky; M A Rudek; S Ahmed; D A Laheru; D Cosgrove; R C Donehower; B Nelkin; D Ball; L A Doyle; H Chen; X Ye; G Bigley; C Womack; N S Azad;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours [J] . B A Wilky, M A Rudek, S Ahmed, British Journal of Cancer . 2015,第1期

机译：使用抗IGF-1R抗体cixutumumab和MEK 1/2抑制剂selumetinib在晚期实体瘤中垂直抑制IGF信号的I期试验
2. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours [J] . Sch?ffskiP., AdkinsD., BlayJ.-Y., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2013,第15期

机译：一项开放标签的2期研究，评估抗IGF-1R抗体cixutumumab在先前已治疗的晚期或转移性软组织肉瘤或尤因家族肿瘤患者中的疗效和安全性
3. Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy [J] . Gradishar William J., Yardley Denise A., Layman Rachel, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第2期

机译：内分泌治疗进展的乳腺癌女性抗IGF-1R（西妥妥单抗）II期随机试验的临床和转化结果
4. A phase I trial of vertical inhibition of IGF signalling using cixutumumab an anti-IGF-1R antibody and selumetinib an MEK 1/2 inhibitor in advanced solid tumours [O] . B A Wilky, M A Rudek, S Ahmed, 2015

机译：使用抗IGF-1R抗体cixutumumab和MEK 1/2抑制剂selumetinib在晚期实体瘤中垂直抑制IGF信号的I期试验
5. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours [O] . B A Wilky, M A Rudek, S Ahmed, 2014

机译：使用Cixutumumab，抗IGF-1R抗体和Selumetinib，MEK 1/2抑制剂，在先进的实体瘤中试验IGF信号传导的垂直抑制的IGF信号的试验

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1|[sol]|2 inhibitor, in advanced solid tumours

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅